Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone

NCT04207255 is registered in ClinicalTrials.gov with Medical University of South Carolina as lead sponsor.

NCT NCT04207255
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04207255 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Study of the Addition of Opaganib to Androgen Antagonists in Patients With Prostate Cancer Progression on Enzalutamide or Abiraterone
Lead sponsor
Medical University of South Carolina
Phase
Phase 2
Overall status
Completed
Start date
March 27, 2020
Completion date
July 31, 2024
Enrollment
69 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

prostate cancer